DSM will provide the process development and cGMP manufacturing services to one of RECEPTA’s lead antibodies at its facilities based in Groningen, The Netherlands.
The financial terms of the agreement have not been disclosed.
DSM started production to supply drug substance materials to be used in the initial clinical trials of the antibody beginning in May of 2012.
RECEPTA Biopharma CEO Jose Perez said the manufacturing agreement with DSM moves one step closer to serving patient needs for the important medical treatment.
"We have developed a productive partnership throughout the course of this project and we are confident that the research that Recepta has carried out to date will be successfully implemented by the industry leading expertise of DSM’s team," Perez added.
According to DSM, its proprietary technologies cut cost, processing times and capital requirements to meet market demand for life saving medications.